STEAP1 and benign prostatic hyperplasia: In contrast, STEAP1 was moderately or highly expressed in the majority of PCa patients (88.89%, 56/63), while low or no expression was demonstrated in most BPH patients (95.12%, 39/41), thus confirming the power of STEAP1 in distinguishing malignant lesions from BPH, with 100% (95% CI 94.9–100.0) sensitivity and 95.1% (95% CI 83.5–99.4) specificity [29].